Acupunct Search

CLOSE


J Acupunct Res > Volume 31(1); 2014 > Article
Kim and Lee: Effects of Paljeong-san Pharmacopuncture on Experimental Rat Model of Benign Prostatic Hyperplasia
See the Original "".

Abstract

Objectives :

The aim of this study is to evaluate the effect of Paljeong-san pharmacopuncture(PJS) on the rat model of benign prostatic hyperplasia(BPH).

Methods :

Rats were divided into 5 groups, with 6 rats in each group. The 5 groups included sham-operated group(sham group), BPH model group(BPH group), finasteride-treated group (fina group), PJS-treated groups(PJS 10 and PJS 100 group). Testosterone was injected subcutaneously to the castrated rats except sham group for BPH model. During 4-week experimental period, finasteride(5 mg/kg) was administrated orally once daily in fina group, PJS in PJS 10(10 mg/kg) and PJS 100(100 mg/kg) group and normal saline in sham and BPH group were injected subcutaneously once daily at Jungwan(CV12).
We checked prostate weights, serum concentration of dihydrotestosterone(DHT), morphologic changes of the prostate, and the amount of expression of the proliferating cell nuclear antigen(PCNA) and 5α-reductase gene to evaluate the effect of PJS after 4-week experimental period.

Results :

  1. PJS and finasteride treatment reduced prostate weights comparing with BPH group, but PJS-treated groups showed no significant changes, unlikely fina group.

  2. PJS-treated groups showed significant degreases in concentration of DHT.

  3. PJS-treated groups showed significant degreases concentration-dependently in the amount of expression of the PCNA and 5α-reductase gene.

  4. PJS treatment showed shrinking of thickness in the prostatic epithelial tissue.

Conclusions :

PJS has the effects that improve the symptoms of BPH through inhibiting proliferation of the prostatic tissues.

Fig. 1.
Effects of Paljeong-San pharmacopuncture adminstration on the concentration of serum dihydrotestosterone(DHT)
Values are expressed as mean±SEM of 6 rats per group.
Sham : sham-operated group.
BPH : BPH model group.
Fina : finasteride-treated group.
10 : PJS(10 mg/kg)-treated group.
100 : PJS(100 mg/kg)-treated group.
Significant difference by Dunnett’s test.
# : p < 0.05 vs. sham group. *** : p < 0.001 vs. BPH group.
acupunct-31-1-95-9f1.gif
Fig. 2.
Effects of Paljeong-San pharmacopuncture(PJS) on prostatic epithelial hyperplasia
H&E staining of prostatic tissue from rats; original magnification 200×. L indicates lumen area and S indicates stromal area. Arrows indicate luminal involutions. The rats in BPH group showed typical histologic changes of reduced glandular luminal area, vacuolated cytoplasm projecting into the glandular lumen and thickened glandular epithelium. In short, most tubule has developed involutions projecting into the lumen, reducing the volume of the inner lumen space compared to others. Administration of PJS for 4 weeks suppressed these typical hyperplastic patterns. PJS, in particular, was more efficacious in suppressing the thickening of epithelium, as compared to the other groups.
acupunct-31-1-95-9f2.gif
Fig. 3.
Effects of Paljeong-San pharmacopuncture on PCNA mRNA expressions in the prostate
Sham : sham-operated group.
BPH : BPH model group.
Fina : finasteride-treated group.
10 : PJS(10 mg/kg)-treated group.
100 : PJS(100 mg/kg)-treated group.
Significant difference by Dunnett’s test.
# : p < 0.05 vs. sham group. *** : p < 0.001 vs. BPH group.
acupunct-31-1-95-9f3.gif
Fig. 4.
Effects of Paljeong-San pharmacopuncture on 5α-reductase mRNA expressions in the prostate
Sham : sham-operated group.
BPH : BPH model group.
Fina : Finasteride-treated group.
10 : PJS(10 mg/kg)-treated group.
100 : PJS(100 mg/kg)-treated group.
Significant difference by Dunnett’s test.
# : p < 0.05 vs. sham group. *** : p < 0.001 vs. BPH group.
acupunct-31-1-95-9f4.gif
Table 1.
Prescription of Paljeong-san
Scientific name Weight(g)
Dianthi Herba 50 g
Rhei Racix Et Rhizoma 50 g
Akebiae Caulis 50 g
Ploygoni Avicularis Herba 50 g
Talcum 50 g
Garseniae Fructus 50 g
Plantaginis Semen 50 g
Glycyrrhizae Radix 50 g
Junci Medulla 50 g

Total amount 450 g
Table 2.
Primer Sequence
Genes Sequence
GAPDH Sense 5′-CGGGAAACCCATCACCATCT-3′
Antisense 5′-CACAAACATGGGGGCATCAG-3′
PCNA* Sense 5′-TCTAGACGTCGCAACTCCGC-3′
Antisense 5′-ATGTCCCAGCAGGCCTCATT-3′
5α-reductase 2 Sense 5′-GACCACAGGCGAGATGCAGA-3′
Antisense 5′-TGTGTTTCCCGTAACTGGCG-3′

glyceraldehyde-3-phosphate dehydrogenase.

* proliferating cell nuclear antigen.

Table 3.
Effects of Paljeong-San Pharmacopuncture Administration on Prostate Weights
Group N Prostate weight(mg)
Sham* 6 0.89 ± 0.12
BPH 6 1.46 ± 0.11
Fina 6 1.15 ± 0.10
PJS 10§ 6 1.43 ± 0.15
PJS 100‖‖ 6 1.36 ± 0.12

Values are expressed as mean±SEM of 6 rats per group.

significant difference by Dunnett’s test. p < 0.05

* sham-operated group.

BPH model group.

finasteride-treated group.

§ PJS(10 mg/kg)-treated group.

‖‖ PJS(100 mg/kg)-treated group.

Table 4.
Effects of Paljeong-San Pharmacopuncture Adminstration on the Concentration of Serum Dihydrotestosterone(DHT)
Group DHT(pg/ml)
Sham 123.35 ± 21.65
BPH* 1356.94 ± 184.93a
Fina 371.02 ± 88.49b
PJS(10 mg/kg) 967.53 ± 141.42b
PJS(100 mg/kg)§ 379.52 ± 127.02b

Data are presented as the means ± SEM of six rats experiments.

Significant difference by Dunnett’s test.

a p < 0.05 vs. sham group.

b p < 0.001 vs. BPH group.

sham-operated group.

* BPH model group.

finasteride-treated group.

PJS(10 mg/kg)-treated group.

§ PJS(100 mg/kg)-treated group.

VI. References

1. American Urological Association. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia(BPH). American Urology Association Education and Research, Inc.. 2010:2–8.

2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–47.
crossref pmid
3. The Korean Urological Association. The Urology. Seoul: Korea Medical Box Publisher. 2001:307–9.

4. Wei J, Calhoun E, Jacobsen S. Urologic disease in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–61.
crossref pmid
5. McConnell J, Roehrborn C, Bautista O, et al. Benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology. 2003;62(3 Supple 1):15–23.
pmid
6. Lee HG, Park YI, Jo SR. Clinical results of transurethral Electro-Vaporization of the prostate. Korean J Urol. 2001;42(8):804–8.

7. Krambeck Amy E, Handa Shelly E, Lingeman James E. Experience with more than 1,000 Holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013;189(4):1415–20.
crossref pmid
8. Doo HK. Donguisingyehag. Seoul: Seongbosa. 2003:705–8.

9. Doo HK. Imsangsingyehagyeongu. Seoul: Seongbosa. 1995:452.

10. Hyun MK, Sin WY, Choi EY, et al. A case of intractable hiccup treated with Paljung-san. J Korean Orient Int Med. 2005;25(2):506–11.

11. Kim SM, Yoo DY. A case report of the effect of Paljeongsna on the female urethral syndrome. Korean J Obstet Gynecol. 2007;20(4):225–33.

12. Song MK, Park SH, Kang JS, et al. Report of four cases of Paljung-san on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Korean Oriental Med. 2010;31(1):153–61.

13. Lim CY, Kim MH, Lee GS, et al. Beneficial effect of Paljeong-san pharmacopuncture treatment combined with peritoneal injection on Glycerol-induced acute renal failure in rabbits. J Korean Pharm Sci. 2010;13(3):73–80.
crossref
14. Lee SY, Kim MH, Cho SI, et al. The effect of Paljeong-San pharmacopuncture treatment on Glycerol-induced acute renal failure in rats. The Journal of Daejeon Oriental Medicine. 2012;21(1):163–74.

15. Korean Society for Sexual Medicine and Andrology. Textbook of Andrology. Seoul: Koonja. 2003:542557–65.

16. Hong SJ. Benign prostatic hyperplasia: Multiple factors for prostate tissue change with aging. Korean J Urol. 2005;46(6):547–54.

17. Lee DH, Lee JS, Kim YS. The effects of Lygodium japonicum on experimental rat model of benign prostatic hyperplasia. J Korean Orient Int Med. 2010;31(3):457–66.

18. Paloma AM, Clemens B, Angelika R, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. PNAS. 2009;106(8):2859–63.
crossref pmid pmc
19. Chung BH. Medical management for benign prostatic hyperplasia. Korean J Urol. 2007;48(3):233–43.
crossref
20. Carson C III, Rittmaster R. The role of dihydro-testosterone in benign prostatic hyperplasia. Urology. 2003;61(4 Supple 1):2–7.
crossref
21. Bartsch G, Rittmaster RS, Klocker H. Dihydro-testosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19(6):413–25.
crossref pmid
22. Woo JH, Kang JY, Kim EK, et al. The effect of short term dutasteride therapy on microvessel density in benign prostatic hyperplasia. Korean J Urol. 2008;49(6):515–9.
crossref
23. Lourenco T, Pcickard R, Vale L, et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ. 2008;337:a1662.
crossref pmid pmc
24. Doo HK. Donguisingyehagyeongu. Seoul: Kyung Hee University Press. 1994:359.

25. Jin S. Taepyeonghyeminhwajegugbang. Taipei: Seonpung Publisher. 1984:175.

26. Heo J. Donguibogam. Seoul: Donguibogam. 2010:346.

27. Professors of Department of Formula Science in College of Korean Medicine. Formula Science. Seoul: Yeongnimsa. 1999:497.

28. Committee on Compilation of Textbook of Korean Society for Acupuncture & Moxibustion. Acupuncture & Moxibustion. Paju: Jipmoondang Publishing Company. 2008:306.

29. Rim HK, Rim JS, Moon HB. A Study on the Relationship between Histologic Composition and Clinical Symptoms in Benign Prostatic Hyperplasia. Korean J Urol. 1994;35(3):230–6.

30. McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol. 1972;107(6):1008–16.
crossref pmid
31. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340–5.
pmid
32. Kim JG, Cho KS, Ahn HJ. The Evaluation of Correlation between the Histologic Composition of BPH and TRUS Findings. Korean J Urol. 1998;39(1):51–6.

33. Jung SI, Oh BR, Ryu SB. Assessing the Effect of Finasteride by Prostate Tissue Composition. Korean J Urol. 2001;42(12):1278–83.

34. Chae SJ, Song HS. The Effects of Cobrotoxin on NF-κB Activation in Human Prostatic Cancer Cell Line(PC-3). J Korean Acupuncture & Moxibustion Medicine Society. 2005;22(5):37–48.

35. Yang CY, Song HS. Bee Venom Inhibits Prostate Cancer Growth in LNCaP Xenografts via Apoptosis. J Pharmacopuncture. 2010;13(1):15–35.
crossref
36. Shin JM, Song HS. Bee Venom Inhibits DU-145 Human Prostate Cancer Cell Growth Through Inactivation of NF-κB. J Korean Acupuncture & Moxibustion Society. 2011;28(3):101–10.

37. Oh HJ, Song HS. Bee Venom Inhibits PC-3 Cell Proliferation Through Induction of Apoptosis Via Inactivation of NF-κB. J Korean Acupuncture & Moxibustion Society. 2010;27(3):1–13.

38. Hur KY, Song HS. Bee Venom Inhibits DU-145 Cell Proliferation Through Induction of Apoptosis. J Korean Acupuncture & Moxibustion Society. 2011;28(3):111–9.
pmid


Article and Issues
For this Journal
For Authors
Ethics
Submit Manuscript
Editorial Office
Gil Korean Medical Hospital, Gachon University
Keunumul-Ro, Chung-Ku, Inchoen 22138, Korea
Tel: +82-70-7606-6353,4    Fax: +82-32-232-3334    E-mail: jared@e-jar.org                

Copyright © 2021 by Korean Acupuncture & Moxibustion Medicine Society. All rights reserved.

Developed in M2PI

Close layer
prev next